
CEO
G. Kelly Martin
Employees
75
Industry
Pharmaceutical Preparation Manufacturing
novan, inc. is a clinical-stage biotechnology company focused on leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. we believe that our ability to conveniently deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to significantly improve patient outcomes in a variety of diseases.
Loading...
Open
0.14
Mkt cap
2.6M
Volume
6.9M
High
0.14
P/E Ratio
-0.11
52-wk high
3.33
Low
0.08
Div yield
N/A
52-wk low
0.08
Portfolio Pulse from Benzinga Insights
July 17, 2023 | 4:17 pm

Portfolio Pulse from Lisa Levin
July 17, 2023 | 4:16 pm
Portfolio Pulse from Benzinga Newsdesk
July 17, 2023 | 3:34 pm
Portfolio Pulse from Vandana Singh
July 17, 2023 | 2:25 pm

Portfolio Pulse from Lisa Levin
July 17, 2023 | 2:02 pm
Portfolio Pulse from Happy Mohamed
July 17, 2023 | 1:18 pm
Portfolio Pulse from Benzinga Newsdesk
July 17, 2023 | 1:12 pm
Portfolio Pulse from Benzinga Newsdesk
July 17, 2023 | 12:48 pm
Portfolio Pulse from Happy Mohamed
July 17, 2023 | 12:27 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.